Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JCOG1213 TOPIC-NEC trial of EP versus IP for advanced digestive system neuroendocrine carcinoma
jRCTs031180005Phase 3Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of etoposide, cisplatin and irinotecan in gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC) (2 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Overall survival. Started Aug 2014; status: completed.
02
Drugs
etoposidecisplatinirinotecan
03
Conditions
gastroenteropancreatic neuroendocrine carcinoma (GEP-NEC)
Beyond the preview
Go deeper on jRCTs031180005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180005.